ERBB2 and breast cancer: In 2016, Mougalian et al. [10] found similar results in a cohort of 1600 stage II/III N+ BC patients: post-NAC negative nodal status rates repartition was 16.4% for luminal BC versus 40.8% for TNBCs and 47.3% for HER-2 positive BC.